NextCell Pharma AB (“NextCell”) announces that another significant milestone has been reached when the last patient, as part of the ProTrans-Repeat active treatment group, today has received their treatment. This implies that all treatments, related to the two ongoing ProTrans studies, have been completed.
NextCell is conducting two parallel clinical trials with the drug candidate ProTrans, with the aim to treat diabetes type-1. ProTrans-Repeat, which was initiated in May 2019, is a continuation trial of ProTrans-1 dose escalation part with the aim of maximizing data collection on repeated treatment, i.e. to find out whether repeated treatment can increase or maintain the effect of ProTrans over a longer period of time with retained safety. This repeat-dose trial includes nine of the patients who completed the dose escalation part of the ProTrans-1 trial as well as another nine patients that serve as a control group, a total of 18 patients. All patients treated with ProTrans in the dose escalating part chose to participate in ProTrans-Repeat to receive a second treatment.
“We are very happy and grateful that the patients who participated in the dose escalation part of ProTrans-1 also wanted to participate in the continuation study, ProTrans-Repeat. It gives us valuable data of repeated treatment,” says Mathias Svahn, CEO.
After today’s treatment, all patients in both ProTrans-1 and ProTrans-Repeat have been treated. Four of nine patients were included in the control group. The remaining five patients are expected to be included during the year.
This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 1st of October 2019.
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595